TP53 co-mutations are associated with elevated PD-L1 expression and high tumor mutational burden in non-small cell lung cancer: insights from comprehensive genomic profiling

Key Points

• Elevated PD-L1 expression and high tumor mutational burden were observed in patients with TP53 co-mutations.
• Among diverse genetic mutations in non-small cell lung cancer, TP53 co-mutations played a pivotal role in outcomes.
• Comprehensive genomic profiling enabled the identification of TP53 co-mutations in lung cancer cases.
• These findings highlight the potential for personalized immunotherapeutic strategies targeting genomic traits.